Why Wave Life Sciences Ltd.’s (WVE) Stock Is Down 5.39%
As of Friday, July 10, Wave Life Sciences Ltd.’s WVE share price has dipped by 5.39%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company’s medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-008, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of liver disease; WVE-N531, an exon splicing oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington’s disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.
Commentary & Analysis
Why Wave Life Sciences Ltd.’s (WVE) Stock Is Up 5.14%
As of Thursday, July 02, Wave Life Sciences Ltd.’s WVE share price has surged by 5.14%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Wave Life Sciences Ltd.’s (WVE) Stock Is Up 5.90%
As of Thursday, June 04, Wave Life Sciences Ltd.’s WVE share price has surged by 5.90%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Wave Life Sciences Ltd.’s (WVE) Stock Is Down 6.15%
As of Tuesday, June 02, Wave Life Sciences Ltd.’s WVE share price has dipped by 6.15%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Wave Life Sciences Ltd.’s (WVE) Stock Is Down 7.09%
As of Monday, May 18, Wave Life Sciences Ltd.’s WVE share price has dipped by 7.09%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Financial Summary
| Share Statistics | WVE | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,110.2 | $569.9 | 46% |
|
| Shares Out (Mil) | 200.2 | 44.8 | 76% |
|
| Institutional Ownership | 99.4% | 84.6% | 88% |
|
| Float (Mil) | 90.1 | 45.1 | 59% |
|
| Beta | -1.32 | 0.67 | 1% |
|
| Avg Daily Volume (000s) | 2,140 | 294 | 83% |
|
| Price Change (52-week) |
(30.7%) | 65.2% | 25% |
|
| Growth | WVE | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 16.3% | 6.7% | 75% |
|
| Net Income (5yr) | (6.4%) | (2.0%) | 32% |
|
| EPS (5yr) | 20.5% | 14.9% | 69 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 13.4% | (14.9%) | 71% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 11 | 12 | 12 | |
| Current EPS | ($0.297) | ($0.838) | ($1.084) | |
| Month Ago EPS | ($0.297) | ($0.838) | ($1.084) | |
| # Rev Up | 0 | 1 | 0 | |
| # Rev Down | 2 | 0 | 1 | |
| Three Months Ago EPS | ($0.305) | ($0.866) | ($1.122) | |
| Year/Year Chg | 128.5% | (30.9%) | (11.7%) | |
| Financials | WVE | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $72 | $230 | 23% |
|
| Net Income (TTM) (Mil) | ($184) | ($11) | 7% |
|
| EPS (TTM) | ($1.031) | ($0.600) | 21% |
|
| Operating Cash Flow (TTM) (Mil) | ($184) | ($6) | 4% |
|
| Net Cash Flow (TTM) (Mil) | $302 | $4 | 88% |
|
| Long-Term Debt (Q1) (Mil) | $7 | $7 | 27% |
|
| Enterprise Value (Q1) (Mil) | $827 | $493 | 39% |
|
| Valuation | WVE | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.17 | 2.89 | 53% |
|
| P/E | na | 20.6 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | WVE | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (164.1%) | 65.9% | 1% |
|
| Net Margin | (255.7%) | (0.2%) | 4% |
|
| ROA | (42.1%) | (25.5%) | 13% |
|
| ROE | (53.7%) | (21.4%) | 15% |
|
| Liabilities to Assets | 12.3% | 35.5% | 7% |
|
| F-Score | 3 | 3 | 19% |
|
Wave Life Sciences Ltd. did not pass any screens on 7/30/2026.
